Evidence map›Paper›PMID 31092842›Full record

ArticleScientific reports2019

The involvement of autotaxin in renal interstitial fibrosis through regulation of fibroblast functions and induction of vascular leakage.

Norihiko Sakai, Gretchen Bain, Kengo Furuichi, Yasunori Iwata, Miki Nakamura, Akinori Hara, Shinji Kitajima, Akihiro Sagara, Taito Miyake, Tadashi Toyama and 5 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis.European respiratory review : an official journal of the European Respiratory Society · 2024
    Review
  6. Review
  7. Article
  8. Article
  9. Design and Development of Autotaxin Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  10. An ATX-LPAiScience · 2021
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. BMS-986020, a Specific LPAAntioxidants (Basel, Switzerland) · 2020
    Article
  16. Review
  17. Article
  18. Article
  19. Loss ofHypertension (Dallas, Tex. : 1979) · 2020
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Norihiko SakaiDivision of Nephrology, Kanazawa University Hospital, Kanazawa, 920-8641, Japan. norin0826@staff.kanazawa-u.ac.jp.
Gretchen BainPharmAkea Inc, San Diego, CA, 92130, USA.
Kengo FuruichiDivision of Nephrology, Kanazawa University Hospital, Kanazawa, 920-8641, Japan.
Yasunori IwataDivision of Nephrology, Kanazawa University Hospital, Kanazawa, 920-8641, Japan.
Miki NakamuraDepartment of Nephrology and Laboratory Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, 920-8641, Japan.
Akinori HaraDivision of Nephrology, Kanazawa University Hospital, Kanazawa, 920-8641, Japan.
Shinji KitajimaDivision of Nephrology, Kanazawa University Hospital, Kanazawa, 920-8641, Japan.
Akihiro SagaraDivision of Nephrology, Kanazawa University Hospital, Kanazawa, 920-8641, Japan.
Taito MiyakeDivision of Nephrology, Kanazawa University Hospital, Kanazawa, 920-8641, Japan.
Tadashi ToyamaDivision of Nephrology, Kanazawa University Hospital, Kanazawa, 920-8641, Japan.
Koichi SatoDivision of Nephrology, Kanazawa University Hospital, Kanazawa, 920-8641, Japan.
Shiori NakagawaDivision of Nephrology, Kanazawa University Hospital, Kanazawa, 920-8641, Japan.
Miho ShimizuDivision of Nephrology, Kanazawa University Hospital, Kanazawa, 920-8641, Japan.
Shuichi KanekoDepartment of System Biology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, 920-8641, Japan.
Takashi WadaDepartment of Nephrology and Laboratory Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, 920-8641, Japan.
Kanazawa University Hospital · JPKanazawa University · JPPatara Pharma (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The accumulation of fibroblasts is a critical step in the development of fibrosis, and lysophosphatidic acid (LPA) promotes fibrosis by regulating multiple fibroblast functions. Autotaxin (ATX) is a key LPA-producing enzyme, and we hypothesized that ATX contributes to the development of renal interstitial fibrosis through LPA-mediated effects on fibroblast functions. In a mouse model of renal interstitial fibrosis induced by unilateral ureteral obstruction (UUO), the levels of renal ATX protein and activity increased with the progression of fibrosis in ligated kidneys, despite concurrent reductions in renal ATX mRNA. UUO enhanced vascular permeability in the renal interstitium, and ATX protein localized to areas of vascular leak, suggesting that vascular leak allowed ATX to enter the renal interstitium. In vitro studies showed that ATX induces the migration and proliferation of renal fibroblasts and enhances the vascular permeability of endothelial monolayers. Finally, pharmacological inhibition of ATX partially attenuated renal interstitial fibrosis. These results suggest that during the development of renal fibrosis, ATX accumulates in the renal interstitium and drives fibroblast accumulation and promotes renal interstitial vascular leak, thereby partially contributing to the pathogenesis of renal interstitial fibrosis. Taken together, ATX inhibition may have the potential to be a novel therapeutic strategy to combat renal interstitial fibrosis.

Indexed as

AnimalsCapillary PermeabilityDisease ProgressionFemaleFibroblastsFibrosisKidneyKidney DiseasesLysophospholipase DMaleMice, Inbred C57BLPhosphoric Diester HydrolasesLysophospholipase DPhosphoric Diester Hydrolases

Identifiers

PMID31092842
PMCPMC6520387
OpenAlexW2945789467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.